Skip to main content
. Author manuscript; available in PMC: 2019 May 19.
Published in final edited form as: Nat Biotechnol. 2018 Nov 19:10.1038/nbt.4297. doi: 10.1038/nbt.4297

Figure 5. hsiRNAsFLT1-2283/2519 treatment lowers sFLT1 serum levels and normalize blood pressure and proteinuria in NHP model of PE.

Figure 5.

a. The timeline for uteroplacental ischemia induction (UPI) model of PE in pregnant baboon. Data collected for hsiRNAsFLT1-2283/2519-treated UPI animals (n=3, mean ±SEM), PBS treated UPI animals (n=6, mean ±SEM), and controls (sham surgery, no UPI) (n=3, mean ±SEM) (***P<0.001, two-way ANOVA; UPI vs hsiRNAsFLT1). b. sFLT1 serum concentration measured by ELISA c. Systolic blood pressure (BP, awake) plotted from telemetry recordings. d. Proteinuria presented as spot protein/creatinine ratio.